doi:10.3969/j.issn.1673-8640.2016.010.015

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 15

[1]	徐欣,黄仁华,周狄,等. 血清β-CTX和OST在骨转移放疗中的临床研究[J]. 临床肿瘤学杂志,2013,18(1):25-29.
[2]	孙燕,管忠震,廖美琳,等. 肺癌骨转移诊疗专家共识(2014版)[J]. 中国肺癌杂志,2014,17(2):52-72.
[3]	LUMACHI F,SANTEUFEMIA DA,DEL CONTE A,et al.Carboxy-terminal telopeptide(CTX) and amino-terminal propeptide(PINP) of type Ⅰ collagen as markers of bone metastases in patients with non-small cell lung cancer[J]. Anticancer Res,2013,33(6):2593-2596.
[4]	王亚萍,黄璇,卢志贤. 血清β-CTX和Total-PⅠNP联检在前列腺癌骨转移监测中的价值[J]. 放射免疫学杂志,2011,24(4):435-437.
[5]	SALEM AM,ZOHNY SF,ABD EL-WAHAB MM,et a1. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer[J]. Clin Biochem,2007,40(16-17):1201-1208.
[6]	刘婷智,王艳玲,吴海鹰,等. 骨标志物N-MID、β-CTX在晚期肺癌骨转移患者中临床意义[J]. 医学信息,2011,24(2):3-4.
[7]	RAMANKULOV A,LEIN M,KRISTIANSEN G,et al.Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer[J]. Prostate,2007,67(3):330-340.
[8]	SEHINDLER F,LAJOLO PP,PINCZOWSKI H,et al.Bone and total alkaline phosphatase for screening skeletal metastasis in patients with solid tumours[J]. Eur J Cancer Care(Engl),2008,17(2):152-156.
[9]	伍建蓉,郑玲,杨红,等. 全身骨显像联合血清骨型碱性磷酸酶诊断肺癌骨转移[J]. 肿瘤研究与临床, 2011,23(5):318-320.
[10]	李晶,朱筠. 维生素D与肿瘤相关疾病的研究进展[J]. 新疆医科大学学报,2009,32(2):222-224.
[11]	陈国军,陆建红,董长林,等. 血清ICTP检测对肺癌骨转移的诊断价值及预后评估[J]. 武警医学,2012,21(2):120-122.
[12]	TANG C,LIU Y,QIN H,et al.Clinical significance of serum BAP,TRACP 5b and ICTP as bone metabolic markers of bone metastasis screening in lung cancer patients[J]. Clin Chim Acta,2013,426:102-107.
[13]	史周印,孙杰,潘赛英,等. 检测NTx、BSP 对唑来膦酸治疗肺癌骨转移的临床意义[J]. 现代肿瘤医学,2011,19(3):470-472.
[14]	李殿波,姜格宁. 肺肿瘤标志物及碱性磷酸酶对肺癌骨转移早期诊断的临床意义[J]. 医学综述,2015,22(8):1487-1488.
[15]	OOI LL,ZHOU H,KALAK R,et al.Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis[J]. Cancer Res,2010,70(5):1835-1844.

组别	例数	TPⅠNP （ng/mL）	β-crosslaps （ng/mL）	ALP （IU/L）	B-ALP （ng/mL）	维生素D （pg/mL）	ⅠCTP （ng/mL）
肺良性疾病组	56	40.50 （14.10~96.70）^*	0.46 （0.11~2.88）	82.00 （46.00~268.00）^*	11.08 （6.06~19.79）^*	7.70 （0.40~25.97）^#	2.20 （0.10~10.00）
肺癌无转移组	115	43.30 （13.60~173.40）^*	0.50 （0.11~1.73）	84 （4.80~1 265.00）^*	11.20 （0.01~28.96）^*	14.30 （4.19~89.33）	2.50 （0.10~12.10）
肺癌骨转移组	101	51.20 （14.40~413.10）	0.61 （0.07~10.06）	97.00 （46.00~272.00）	14.29 （6.09~48.49）	15.20 （5.96~47.50）	2.40 （0.10~10.50）

组别	例数	TPⅠNP （ng/mL）	β-crosslaps （ng/mL）	ALP （IU/L）	B-ALP （ng/mL）	维生素D （pg/mL）	ⅠCTP （ng/mL）
肺良性疾病组	56	40.50 （14.10~96.70）^*	0.46 （0.11~2.88）	82.00 （46.00~268.00）^*	11.08 （6.06~19.79）^*	7.70 （0.40~25.97）^#	2.20 （0.10~10.00）
肺癌无转移组	115	43.30 （13.60~173.40）^*	0.50 （0.11~1.73）	84 （4.80~1 265.00）^*	11.20 （0.01~28.96）^*	14.30 （4.19~89.33）	2.50 （0.10~12.10）
肺癌骨转移组	101	51.20 （14.40~413.10）	0.61 （0.07~10.06）	97.00 （46.00~272.00）	14.29 （6.09~48.49）	15.20 （5.96~47.50）	2.40 （0.10~10.50）

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 15

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.